What changed
Deals & ownershipMichael J. Farrell, chair and CEO of ResMed, filed a notice of a proposed sale of 4,993 shares on November 9, 2026. On November 11, several company executives and directors conducted stock transactions to cover tax obligations. These reports reflect standard corporate compensation management procedures.

What changedResMed reported GAAP earnings per share (EPS) of $2.92 for the first quarter of fiscal year 2027, up 23% from the prior year. Adjusted EPS was $2.91, up 14%.

What changedResMed reported that for fiscal year 2026 revenue grew 8% in constant currency, free cash flow exceeded $1.6 billion, and the company returned more than $1 billion to shareholders. It completed the acquisition of Noctrix Health for $340 million, and proceeds from the MatrixCare sale are being used for an accelerated share repurchase (ASR).

Upcoming events
As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →
Company history
October 2026
RESMED INC: 12 recorded developments from 1 official source in 2026-10.
- 2026-10-30: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 1,414,814,000 USD (1.4 billion; 1,415 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,335,582,000 USD (1.3 billion; 1,336 million); change +5.9% Source
- 2026-10-30: Gross profit (us-gaap:GrossProfit), quarter 2026-07-01 to 2026-09-30: 870,567,000 USD (871 million); same period a year earlier (2025-07-01 to 2025-09-30): 817,664,000 USD (818 million); change +6.5% Source
- 2026-10-30: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 452,984,000 USD (453 million); same period a year earlier (2025-07-01 to 2025-09-30): 446,537,000 USD (447 million); change +1.4% Source
- 2026-10-30: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 418,413,000 USD (418 million); same period a year earlier (2025-07-01 to 2025-09-30): 348,536,000 USD (349 million); change +20% Source
- 2026-10-30: Dividends per share (us-gaap:CommonStockDividendsPerShareDeclared), quarter 2026-07-01 to 2026-09-30: 0.66 USD/shares; same period a year earlier (2025-07-01 to 2025-09-30): 0.6 USD/shares; change +10% Source
- 2026-10-30: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 102,860,000 USD (103 million); same period a year earlier (2025-07-01 to 2025-09-30): 89,479,000 USD (89 million); change +15% Source
- 2026-10-30: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), quarter 2026-07-01 to 2026-09-30: 422,422,000 USD (422 million); same period a year earlier (2025-07-01 to 2025-09-30): 457,321,000 USD (457 million); change -7.6% Source
- 2026-10-30: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), quarter 2026-07-01 to 2026-09-30: 48,740,000 USD (49 million); same period a year earlier (2025-07-01 to 2025-09-30): 42,965,000 USD (43 million); change +13.4% Source
- 2026-10-30: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 1,010,742,000 USD (1 billion; 1,011 million); previous balance (2026-06-30): 1,469,234,000 USD (1.5 billion; 1,469 million); change -31.2% Source
- 2026-10-30: Total assets (us-gaap:Assets), as of 2026-09-30: 8,211,811,000 USD (8.2 billion; 8,212 million); previous balance (2026-06-30): 8,965,950,000 USD (9 billion; 8,966 million); change -8.4% Source
- 2026-10-30: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 2,264,121,000 USD (2.3 billion; 2,264 million); previous balance (2026-06-30): 2,380,557,000 USD (2.4 billion; 2,381 million); change -4.9% Source
- 2026-10-30: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 5,947,690,000 USD (5.9 billion; 5,948 million); previous balance (2026-06-30): 6,585,393,000 USD (6.6 billion; 6,585 million); change -9.7% Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
How expectations played out
2 of 3 expectations checked against later reports
Mostly AI assessments, provisional; an editor's decision replaces them. Not a rating of the shares.
Checked against later reports
Plan to return more than $1.85 billion to stockholders in fiscal year 2027.
Said October 1, 2026 · Period named: fiscal year 2027 · Source · Our article
AI assessment, provisional later reports are consistent with it (as of October 29, 2026) · Later article
Expect to repurchase approximately $1.5 billion of ResMed shares over fiscal 2027, inclusive of the accelerated share repurchase.
Said October 1, 2026 · Period named: fiscal 2027 · Source · Our article
AI assessment, provisional later reports are consistent with it (as of October 29, 2026) · Later article
Open
ResMed plans to continue building its core sleep and breathing health businesses by extending the reach of its digital health ecosystem and connecting more people worldwide with home-based treatment.
Said October 29, 2026 · Period named: rest of fiscal year 2027 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Changes in risk factors
The 10-Q filed October 30, 2026 compared with the 10-Q filed May 1, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (29)
- | 191,038 | | $ | 764 | | $ | 2,190,614 | | (46,798) | | $ | (2,778,591) | | $ | 7,255,121 | | $ | (82,515) | | $ | 6,585,393
- | 191,081 | | $ | 764 | | $ | 2,133,418 | | (50,442) | | $ | (3,633,335) | | $ | 7,578,580 | | $ | (131,737) | | $ | 5,947,690
- | 190,311 | | $ | 761 | | $ | 2,033,599 | | (43,926) | | $ | (2,073,292) | | $ | 6,081,490 | | $ | (74,699) | | $ | 5,967,859
Dropped (59)
- Other intangible assets, net (note 3) | 425,185 | | | 464,861
- | $ | 1,260,516 | | | $ | 1,130,575 | | | $ | 3,685,900 | | | $ | 3,323,905
- Net revenue | 1,431,406 | | | 1,291,736 | | | 4,189,796 | | | 3,798,334
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| August 17, 2026 | Change of auditor (8-K item 4.01) | 8-K |
| August 17, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| November 17, 2026 | De Witte Jan | Planned sale 10b5-1 plan | 429 | — | $101,673 | SEC |
| November 9, 2026 | Michael J. Farrell | Sale 10b5-1 plan notice filed | 4,993 | $235.35 | $1,175,089 | SEC |
| October 23, 2026 | Michael J Rider | Sale 10b5-1 plan notice filed | 400 | $255.00 | $102,000 | SEC |
| October 7, 2026 | Michael J. Farrell | Sale 10b5-1 plan notice filed | 4,991 | $226.33 | $1,129,637 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 11,954,239 | $2,643,082,249 | -2.9% | Q3 2026 |
| State Street | 6,519,249 | $1,441,405,954 | -2.4% | Q3 2026 |
| Geode Capital Management | 4,420,200 | $973,889,075 | +1.6% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 664,714 | $129,539,464 | — | Q2 2026 |
| Citadel Advisors | 527,861 | $116,710,068 | +3.9% | Q3 2026 |
| Two Sigma Investments | 295,657 | $65,369,763 | -28.1% | Q3 2026 |
| Fidelity (FMR) | 251,972 | $55,711,168 | +16.3% | Q3 2026 |
| Millennium Management | 100,045 | $22,119,950 | -51.1% | Q3 2026 |
| Renaissance Technologies | 93,920 | $20,765,712 | +5,697.5% | Q3 2026 |
| Wellington Management | 93,564 | $20,687,001 | +15.2% | Q3 2026 |
| Bridgewater Associates | 14,487 | $3,203,076 | -78.5% | Q3 2026 |
| D. E. Shaw & Co. | 5,819 | $1,286,581 | -4.9% | Q3 2026 |
| T. Rowe Price | 462,455 | $102,250 | +24.4% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.